Payment overview · 2025
General Payments
$727.34
37 reported records · 10 companies
Healthcare provider profile · identity verified
Mark D Erhardt, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BARTLESVILLE, OK · NPI 1770546640
Verified facts
What the public records show
CMS Open Payments records show Mark D Erhardt, D.O. received $727.34 in general payments during 2025 across 37 reported records.
Amgen Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.94 | 20.2% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $123.74 | 17.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.79 | 13.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.22 | 12.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.31 | 8.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.70 | 8.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.52 | 8.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.93 | 4.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $31.03 | 4.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.16 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.34 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $128.24 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $123.74 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $123.59 | 6 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $95.79 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.52 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.52 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.42 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.42 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 416 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 143 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 251 | 99 |
| Lisinopril | Lisinopril | 236 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 85 |
| Omeprazole | Omeprazole | 212 | 81 |
| Trazodone Hcl | Trazodone Hcl | 199 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 67 |
| Gabapentin | Gabapentin | 174 | 62 |
| Tramadol Hcl | Tramadol Hcl | 160 | 53 |
| Alprazolam | Alprazolam | 159 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 63 |
| Mounjaro | Tirzepatide | 153 | 24 |
| Metformin Hcl | Metformin Hcl | 146 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 51 |
| Montelukast Sodium | Montelukast Sodium | 135 | 43 |
| Simvastatin | Simvastatin | 133 | 51 |
| Fenofibrate | Fenofibrate,micronized | 132 | 51 |
| Furosemide | Furosemide | 122 | 49 |
| Potassium Chloride | Potassium Chloride | 120 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 40 |
| Celecoxib | Celecoxib | 98 | 38 |
| Valsartan | Valsartan | 97 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 36 |
| Losartan Potassium | Losartan Potassium | 90 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 42 |
| Meloxicam | Meloxicam | 89 | 38 |
| Azithromycin | Azithromycin | 86 | 67 |
| Pregabalin | Pregabalin | 82 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 80 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 19 |
| Prednisone | Prednisone | 68 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 19 |
| Donepezil Hcl | Donepezil Hcl | 62 | 22 |
| Jardiance | Empagliflozin | 62 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 16 |
| Fenofibrate | Fenofibrate | 61 | 17 |
| Trulicity | Dulaglutide | 59 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Lorazepam | Lorazepam | 52 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | 16 |
| Carvedilol | Carvedilol | 44 | 22 |
| Estradiol | Estradiol | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | 14 |
| Spironolactone | Spironolactone | 43 | 17 |
| Allopurinol | Allopurinol | 42 | 15 |
| Ondansetron Odt | Ondansetron | 42 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Naproxen | Naproxen | 39 | 29 |
| Eliquis | Apixaban | 38 | 13 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Atenolol | Atenolol | 36 | 13 |
| Finasteride | Finasteride | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Temazepam | Temazepam | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Famotidine | Famotidine | 27 | 12 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 11 |
| Fluconazole | Fluconazole | 25 | 16 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 14 |
| Baclofen | Baclofen | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 16 |
| Ozempic | Semaglutide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Linzess | Linaclotide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.34 · 37 records | Amgen Inc. | AIRSUPRA, BOTOX, CAPLYTA, Fluad, Flucelvax, JARDIANCE, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error